Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

814 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2018-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Imatinib 400mg daily is the current NICE-approved standard treatment for newly diagnosed Chronic Myeloid Leukaemia (CML). 5 yr follow up of CML patients treated in this way indicates an 89% probability of progression-free survival. Imatinib is not tolerated or effective in some patients however, and a proportion of patients become resistant to the drug. SPIRIT 2 study aims to establish whether a new drug, dasatinib, is superior to imatinib in terms of event free survival and therefore will be an effective first-line therapy for newly-diagnosed CML patients. This study will also provide crucial long-term survival, quality of life and health economic data to assist health care providers and managers to determine the most cost-effective drug therapy for CML.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response

NCT00210119

Myeloid Leukemia, Chronic

TERMINATED PHASE2

Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)

NCT00514488

Chronic Myeloid Leukemia

COMPLETED PHASE3

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00471497

Myelogenous Leukemia, Chronic

COMPLETED PHASE3

Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial

NCT06646978

Chronic Myeloid Leukemia (CML)

ENROLLING_BY_INVITATION

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

NCT00054431

Accelerated Phase Chronic Myelogenous Leukemia Blastic Phase Chronic Myelogenous Leukemia Childhood Chronic Myelogenous Leukemia +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myeloid Leukemia, Chronic, Chronic Phase

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A - Imatinib

Imatinib 400mg daily

Group Type ACTIVE_COMPARATOR

Imatinib

Intervention Type DRUG

Oral Imatinib 100mg daily

Arm B - Dasatinib

Dasatinib 100mg daily

Group Type EXPERIMENTAL

Dasatinib

Intervention Type DRUG

Oral Dasatinib 100mg daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imatinib

Oral Imatinib 100mg daily

Intervention Type DRUG

Dasatinib

Oral Dasatinib 100mg daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gleevec/Gleevic Sprycel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients 18 years or over.
2. Patients must have all of the following:

* be enrolled within 3 months of initial diagnosis of CML-CP (date of initial diagnosis is the date of first cytogenetic analysis)
* cytogenetic confirmation of the Philadelphia chromosome or variants of (9;22) translocations
* patients may have secondary chromosomal abnormalities in addition to the Philadelphia chromosome.
* \< 15% blasts in peripheral blood and bone marrow;
* \< 30% blasts plus promyelocytes in peripheral blood and bone marrow;
* \< 20% basophils in peripheral blood,
* 100 x 109/L platelets or greater
* no evidence of extramedullary leukaemic involvement, with the exception of the hepatosplenomegaly.
3. Written voluntary informed consent.

Exclusion Criteria

1. Patients with Ph-negative, BCR-ABL-positive, disease are NOT eligible for the study.
2. Any prior treatment for CML with: any tyrosine kinase inhibitor (eg imatinib, dasatinib); busulphan; interferon-alpha; homoharringtonine; cytosine arabinoside; any other investigational agents (hydroxycarbamide and anagrelide are the only drugs permitted). NB patients will be ineligible for the study if they have received ANY prior therapy with interferon-alpha or imatinib. NO exceptions.
3. Patients who received prior chemotherapy, including regimens used in peripheral blood progenitor cells (PBPCs) mobilisation for haematopoietic progenitor-cell transplantation. (It is allowable to collect unmobilised PBPCs at diagnosis.)
4. Patient who have had any form of prior haemopoietic stem cell transplant, either autograft or allograft.
5. Patients with an ECOG Performance Status Score of 2 or less.
6. Patients with serum bilirubin, SGOT/AST, SGPT/ALT, or creatinine concentrations \> 2.0 x the institutional upper limit of the normal range (IULN).
7. Patients with International normalized ratio (INR) or partial thromboplastin time (PTT) \> 1.5 x IULN, with the exception of patients on treatment with oral anticoagulants.
8. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, infection, angina, or Grade 3/4 cardiac problems as defined by the New York Heart Association Criteria.
9. Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required.
10. Patients who have undergone major surgery within 4 weeks of Study Day 1, or who have not recovered from prior major surgery.
11. Patients who are:

* pregnant,
* breast feeding,
* of childbearing potential without a negative pregnancy test prior to Study Day 1, and
* male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential).
12. Patients with a history of another malignancy either currently or within the past five years, with the exception of basal cell skin carcinoma or cervical carcinoma in situ.
13. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No